Contribution of Wine Components on Hydroxytyrosol Body Concentrations and Biological Effects

Phase 1

Completed

• Conditions: Contribution of Wine Components in Hydroxytyrosol Formation
• Interventions: Other: Water; Dietary Supplement: Alcoholized wine; Dietary Supplement: De-alcoholized wine; Dietary Supplement: Ethanol

• Registration Number: NCT01790672
• Lead Sponsor: Parc de Salut Mar

Brief Summary

The study is aimed at establishing the contribution of wine components on hydroxytyrosol body concentrations and biological effects.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-05
• Study First Submitted: 2013-02-11
• Study First Submitted QC: 2013-02-11
• Study First Posted: 2013-02-13
• Primary Completion: 2013-09
• Study Completion: 2013-09
• Status Verified: 2014-07
• Last Update Submitted: 2014-07-23
• Last Update Posted: 2014-07-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Understanding and accepting the study procedures and signing the informed consent.
• Male and female volunteers aged 18 to 55 years. No fixed sex ratio has been established.
• Clinical history and physical examination demonstrating no organic or psychiatric disorders.
• The ECG and general blood and urine laboratory tests performed before the study should be within normal ranges. Minor or occasional changes from normal ranges are accepted if, in the investigator's opinion, considering the current state of the art, they are not clinically significant, are not life-threatening for the subjects and do not interfere with the product assessment. These changes and their non-relevance will be justified in writing specifically.
• The body mass index (BMI=weigh/height2) will range from 19 to 25 kg/m2, and the weight from 50 to 100 kg. 25-27 could be accepted.
• Women with regular menstrual cycle of 26-32 days.
• Subjects socially drinking and who had ingested wine at least once.

Exclusion Criteria

• Not meeting the inclusion criteria.
• History or clinical evidence of gastrointestinal, liver, renal or other disorders which may lead to suspecting a disorder in drug absorption, distribution, metabolism or excretion, or that suggest gastrointestinal irritation due to drugs.
• History or clinical evidence of psychiatric disorders, alcoholism, drug abuse, or regular use of psychoactive drugs.
• Blood donation in the previous 8 weeks or participation in other clinical trials with drugs in the previous 12 weeks.
• Having suffered any organic disease or major surgery in the three months prior to the study start.
• Subjects with intolerance or serious adverse reactions to ethanol.
• Regular use of any drug in the month prior to the study sessions, except for vitamins or diet supplements, that, in the opinion of the principal investigator or co-investigators designated by him, do not involve a risk for the subject and do not interfere with the study objectives. In this case they should be discontinued from one week before the experimental sessions to the end of them. The treatment with single or limited doses of symptomatic medicinal products in the week prior to the study sessions will not be a reason for exclusion if it is calculated that it has been cleared completely the day of the experimental session.
• Taking more than 20 g of alcohol a day in women and more than 30 g in men.
• Taking more than 5 coffees, teas, cola drinks or other stimulating drinks or with xanthines daily in the 3 months prior to the study start.
• Subjects unable to understand the nature, consequences of the study and the procedures requested to be followed.
• Smokers or ex-smokers of less than one year.
• Subjects with positive serology to Hepatitis B, C or HIV.
• Pregnant or nursing women or positive pregnancy test in urine. Women not undertaking to follow reliable contraceptive measures during the study (such as abstinence, hormonal contraceptives, intrauterine devices, double-barrier methods or vasectomised partner).
• Women with amenorrhea or premenstrual syndrome of moderate or severe intensity.
• Nonsteroidal anti-inflammatory drugs, antioxidants or vitamins consumption in the last 2 weeks.
• Total cholesterol >6.00 mmol/l (240 mg/dl) or triglycerides >2.26 mmol/l (200 mg/dl).
• Vegetarians or subjects following aberrant diets.
• Physical exercise of >2h/day or >3000 kcal /week.

To be eligible, the subjects must agree to follow a poor polyphenols diet in the 72 hours prior to the start of each session and until 24 hours after.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Water	Water	Lemon-flavored water. 293 ml in pilot A, 147 ml in pilot B, 235 ml in pilot C, 147 ml in the definitive study.
Alcoholized wine	Alcoholized wine	Wine 13º in pilot A (293 ml), B (147 ml) and the definitive study (147 ml). Corresponding to 30 g of ethanol in pilot A, 15 g of ethanol in pilot B and 15 g of ethanol in the definitive study. Wine 8º in pilot C (235 ml). Corresponding to 15 g of ethanol.
De-alcoholized wine	De-alcoholized wine	Wine 0º. Pilot A: 293ml; pilot B: 147 ml; pilot C: 235 ml; definitive study: 147 ml. Corresponding to 0 g of ethanol.
Ethanol	Ethanol	Ethanol 13º in pilot A (293 ml), B (147 ml) and definitive study (147 ml). Corresponding to 30 g of ethanol in pilot A, 15 g of ethanol in pilot B and in the definitive study. Ethanol 8º in pilot C (235 ml). Corresponding to 15 g of ethanol. Ethanol was administered as a single dose of Vodka Absolut (40º) diluted in lemon-flavored water.

Primary Outcome Measures

Name	Time	Method
Hydroxytyrosol biological fluids concentrations	0-24h after administration	Hydroxytyrosol concentrations in plasma and urine

Secondary Outcome Measures

Name	Time	Method
Oxidation biomarkers of proteins and lipids	0-24h after administration
Platelets monoamine oxidase-B activity	Baseline
Vital signs	0-24h after administration	Blood pressure, oral temperature and heart rate
Dopamine metabolites concentrations	0-24h after administration	Dopamine metabolites recovery in urine
Breath ethanol	30 min after administration	Breath ethanol concentration
Ethanol concentration	0-6h after administration	Ethanol blood concentrations
Subjective drunkenness	0-6h after administration	Ethanol subjective effects measured using a visual analog scale
Ethanol metabolites concentrations	0-24h after administration	Ethanol metabolites recovery in urine
Gene expression of genes related with receptors and regulators/oxidative stress and antioxidant defence	Baseline
Psychomotor performance (DSST)	0-6h after administration	Psychomotor performance assessed by means of Digit symbol substitution test (DSST)

Trial Locations

Locations (1)

Parc de Salut Mar; 🇪🇸 Barcelona, Spain